

# Judith E Karp

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9457300/judith-e-karp-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

865  
citations

12  
h-index

19  
g-index

19  
ext. papers

959  
ext. citations

5.6  
avg, IF

3.39  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 18 | CDK2-Mediated Upregulation of TNF $\alpha$ s a Mechanism of Selective Cytotoxicity in Acute Leukemia. <i>Cancer Research</i> , <b>2021</b> , 81, 2666-2678  | 10.1 | 1         |
| 17 | Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. <i>Leukemia Research</i> , <b>2021</b> , 110, 106707 | 2.7  | 1         |
| 16 | Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). <i>Leukemia Research</i> , <b>2018</b> , 72, 92-95  | 2.7  | 19        |
| 15 | Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. <i>Stem Cells Translational Medicine</i> , <b>2017</b> , 6, 840-850   | 6.9  | 5         |
| 14 | A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 697-706   | 12.9 | 40        |
| 13 | 4EBP1/c-MYC/PUMA and NF- $\kappa$ B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. <i>Blood</i> , <b>2016</b> , 127, 2711-22  | 2.2  | 42        |
| 12 | Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , <b>2015</b> , 100, 1172-9   | 6.6  | 70        |
| 11 | Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. <i>Leukemia Research</i> , <b>2015</b> , 39, 1312-8.   | 2.7  | 70        |
| 10 | Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 340-8  | 2.2  | 67        |
| 9  | New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6233-41   | 12.9 | 16        |
| 8  | Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 198-207  | 4.5  | 6         |
| 7  | Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6723-31   | 12.9 | 87        |
| 6  | Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5364-73  | 12.9 | 47        |
| 5  | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. <i>Blood</i> , <b>2007</b> , 109, 2781-90   | 2.2  | 253       |
| 4  | A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. <i>Blood</i> , <b>2007</b> , 110, 1762-9  | 2.2  | 76        |
| 3  | Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. <i>Blood</i> , <b>2006</b> , 107, 2501-6   | 2.2  | 65        |
| 2  | Farnesyl transferase inhibition in hematologic malignancies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2005</b> , 3 Suppl 1, S37-40   | 7.3  |           |

|   |   |     |   |
|---|---|-----|---|
| 1 | The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?. <i>EJHaem</i> , | 0.9 | 0 |
|---|---|-----|---|